In Silico Pharmacological Evaluation of Azadirachta indica Phytochemicals Targeting Thalassemia-Associated Genes and Proteins
- 7 January 2026
- journal article
- Published by World Scientific Pub Co Pte Ltd in Journal of Computational Biophysics and Chemistry
- Vol. 25 (11) , 2897-2910
Abstract
Thalassemia is an inherited hemoglobin disease characterized by persistent anemia, oxidative and iron overload due to transfusion, creating severe clinical and economic issues in South Asia. The adverse effects and adverse effects of current treatment options highlight the need to have safer and multi-target options. In this study, a comprehensive in silico pharmacoinformatic methodology was applied to determine the therapeutic value of Azadirachta indica (Neem) phytochemicals on thalassemia-related targets. One hundred and five phytocompounds were shortlisted, and the number of those passing drug-likeness and ADMET filters evaluated at SwissADME, MolSoft (v6.8) and ADMETlab 3.0 was 350. The intersecting genes were predicted by target prediction with SwissTargetPrediction and functionally enriched with the help of DAVID (v6.8) and KEGG (v113.0). Significantly enriched pathways were Lipid and Atherosclerosis (Benjamini [ ] 0.0236), Apoptosis ([ ] 0.043) and Chemical Carcinogenesis ([ ] 0.00167). The central hub genes were TNF, TP53, PPARG, CYP3A44 and found by the network analysis with the help of STRING (v11.5) and Cytoscape (v3.10.0). Molecular docking was done using PyRx (v0.9.8) with AutoDock Vina (v1.2.3) being implemented. The highest affinity of the screened compounds was found to be Naringenin, with a binding energy of −9.8 kcal/mol (PDB ID: 1v04), and it was greater than that of Hydroxyurea (−8.9 kcal/mol), Deferiprone (−5.3 kcal/mol) and Deferasirox (−5.3 kcal/mol). Quercetin, Luteolin and Genistein had a good binding profile with the presence of stable hydrogen bonding and [ ]–[ ] interactions as illustrated in PyMOL (v2.5). This cumulative computational pipeline lays significant evidence that phytochemicals derived from Neem are prime multi-target lead compounds to use as adjuncts in the treatment of thalassemia. These findings require further confirmation through molecular dynamics simulations and experimental confirmation.Keywords
Funding Information
- Deanship of Scientific Research, Princess Nourah Bint Abdulrahman University (PNURSP2026R437)
This publication has 47 references indexed in Scilit:
- Exploring the potential mechanism of Tinospora cordifolia in cancer treatment: A network pharmacology and molecular docking approachIn Silico Research in Biomedicine, 2025
- Traditional to modern perspectives on Neem (Azadirachta indica): A gateway to bioactive compounds, sustainable agrochemicals and industrial applicationsIndustrial Crops and Products, 2025
- RETRACTED: Proteomic hub proteins CDKN2B, TRAPPC2L, WFS1, and ARPP19 drive biochemical recurrence and metastatic progression in prostate cancer: Protein macromolecule actionInternational Journal of Biological Macromolecules, 2025
- Analysis of the anti-Alzheimer potential of bioactive compounds from Citrus hystrix DC. peel, leaf, and essential oil by network pharmacologyHeliyon, 2024
- Regulatory mechanism and therapeutic potentials of naringin against inflammatory disordersHeliyon, 2024
- Αlpha-thalassemia: A practical overviewBlood Reviews, 2024
- Global distribution of β-thalassemia mutations: An updateGene, 2023
- Evaluation of therapeutic potentials of selected phytochemicals against Nipah virus, a multi-dimensional in silico study3 Biotech, 2023
- Interaction of luteolin, naringenin, and their sulfate and glucuronide conjugates with human serum albumin, cytochrome P450 (CYP2C9, CYP2C19, and CYP3A4) enzymes and organic anion transporting polypeptide (OATP1B1 and OATP2B1) transportersBiomedicine & Pharmacotherapy, 2022
- Exploring the role of Azadirachta indica (neem) and its active compounds in the regulation of biological pathways: an update on molecular approach3 Biotech, 2021